Clinical trial guidelines for pharmacological treatment of irritable bowel syndrome (Q35216885)

7 August 2017

1 reference

title

Clinical trial guidelines for pharmacological treatment of irritable bowel syndrome (English)

1 reference

7 August 2017

main subject

irritable bowel syndrome

1 reference

Corazziari E

1 reference

7 August 2017

Bytzer P

1 reference

7 August 2017

Delvaux M

1 reference

7 August 2017

Holtmann G

1 reference

7 August 2017

Malagelada JR

1 reference

7 August 2017

Morris J

1 reference

7 August 2017

Muller-Lissner S

1 reference

7 August 2017

Spiller RC

1 reference

7 August 2017

Tack J

1 reference

7 August 2017

Whorwell PJ

1 reference

7 August 2017

language of work or name

English

0 references

publication date

1 September 2003

1 reference

Alimentary Pharmacology & Therapeutics

7 August 2017

published in

1 reference

7 August 2017

1 reference

7 August 2017

1 reference

7 August 2017

page(s)

569-580

1 reference

Irritable bowel syndrome in general practice: prevalence, characteristics, and referral

7 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01709.X

Problems and challenges in the design of irritable bowel syndrome clinical trials: experience from published trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01709.X

Predictive value of the Rome criteria for diagnosing the irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01709.X

Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01709.X

Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01709.X

Characteristics of patients with irritable bowel syndrome recruited from three sources: implications for clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01709.X

Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized, controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01709.X

Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01709.X

Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01709.X

Patient‐perceived severity of irritable bowel syndrome in relation to symptoms, health resource utilization and quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01709.X

Long term efficacy, safety, and tolerabilitity of low daily doses of isosmotic polyethylene glycol electrolyte balanced solution (PMF-100) in the treatment of functional chronic constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01709.X

The menstrual cycle affects rectal sensitivity in patients with irritable bowel syndrome but not healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01709.X

Does lactose maldigestion really play a role in the irritable bowel?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01709.X

A comparison of symptoms after the consumption of milk or lactose-hydrolyzed milk by people with self-reported severe lactose intolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01709.X

Survey of the AGA membership relating to patients with functional gastrointestinal disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01709.X

Epidemiology of irritable bowel syndrome in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01709.X

Controlled treatment trials in the irritable bowel syndrome: a critique.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01709.X

Symptoms of psychologic distress associated with irritable bowel syndrome. Comparison of community and medical clinic samples

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01709.X

Gender differences in irritable bowel symptoms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01709.X

Psychosocial factors in the irritable bowel syndrome. A multivariate study of patients and nonpatients with irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01709.X

One-year follow-up of newly diagnosed irritable bowel syndrome patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01709.X

The relationship of current psychiatric disorder to functional disability and distress in patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01709.X

Psychosocial factors are associated with health care seeking rather than diagnosis in irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01709.X

Screening for adult coeliac disease - which serological marker(s) to use?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01709.X

10.1046/J.1365-2036.2003.01709.X

21 January 2018

Identifiers

DOI

1 reference

7 August 2017

1 reference